Thursday
SESSION XIV: CRITICAL EVALUATION OF CAROTID ARTERY STENTING (CAS) (6-MINUTE TALKS)
SESSION XIV SCHEDULE
1:30 PM - 1:36 PM CAS vs. CEA vs. Medical Treatment: How To Choose Without Bias
  Presenters(s): Michael R. Jaff, D.O.  
1:37 PM - 1:43 PM How To Pick By Duplex Ultrasonography Asymptomatic Patients Who Will Develop Symptoms And Who Need Treatment
  Presenters(s): Jose Fernandes e Fernandes, MD, PhD, FRCS (Eng), FACS  
1:44 PM - 1:50 PM Carotid Plaque Characteristics And Their Therapeutic And Prognostic Implications
  Presenters(s): Giorgio M. Biasi, M.D.  
1:51 PM - 1:57 PM CAS Is Emerging As Best And Safest When Carotid Intervention May Not Be Needed At All: Is CEA Now Best After All And Will This Change With Better Devices?
  Presenters(s): Frank J. Criado, M.D.  
1:58 PM - 2:04 PM Are Statins Indicated Before CEA: How Long Before Should They Be Started?
  Presenters(s): Bruce A. Perler, M.D., M.B.A.  
2:05 PM - 2:11 PM Statins Prevent Strokes: The SPARCLE Trial: Does It Render NASCET, ECST, ACAS, ACST Obsolete And Mandate New Trials Of Best Medical Treatment Versus CEA And CAS?
  Presenters(s): Henrik Sillesen, MD, DMSc  
2:12 PM - 2:18 PM What Lesion Characteristics Are Associated With Increased Risk Of Stroke With CAS: Long Lesions Are Dangerous
  Presenters(s): Michel S. Makaroun, M.D. / Mark H. Wholey, M.D.  
2:19 PM - 2:25 PM CAS Can Be Done Without Cerebral Embolic Protection: How Can This Be Done Safely?
  Presenters(s): Franco Perona, M.D.  
2:26 PM - 2:32 PM Strategies For Avoiding Embolic And Non-Embolic Stroke With CAS: How To Choose An Embolic Protection Device
  Presenters(s): Sumaira Macdonald, MBChB (Comm), FRCP, FRCR, PhD  
2:33 PM - 2:40 PM Panel Discussion
Moderator(s): Jean-Pierre Becquemin, M.D., F.R.C.S. / Keith D. Calligaro, M.D.  
2:40 PM - 2:46 PM Debate: CAS Is Currently Being Underutilized Viz A Viz Medical Treatment And CEA: Reflections On CAS By A Master Who Has Done More Than 1,000
  Presenters(s): Mark H. Wholey, M.D.  
2:47 PM - 2:53 PM Debate: CAS Is Currently Being Overutilized Viz A Viz Medical Treatment And CEA
  Presenters(s): Peter R.F. Bell, M.D., F.R.C.S., D.S.C., K.B.E.  
2:54 PM - 3:00 PM Update On The German SPACE Trial: One Year Outcome Results With Subgroup Analysis: CEA vs. CAS In Symptomatic Patients
  Presenters(s): Hans-Henning Eckstein, M.D., Ph.D.  
3:01 PM - 3:07 PM The EVA-3S Trial Was Flawed Because The Interventionists Were Inexperienced And Not Representative Of The Best: One Participantís View
  Presenters(s): Max Amor, M.D.  
3:08 PM - 3:14 PM The EVA-3S Trial Was Not Flawed Because The Interventionists Were State-Of-The-Art And Got Better Outcomes In Symptomatic Patients Than In The CAPTURE Trial: What Conclusion Should We Reach: The View Of Other Participants
  Presenters(s): Jean Michel Bartoli, M.D. / Philippe Piquet, M.D.  
3:15 PM - 3:21 PM Most Strokes Following CAS Occur After Embolic Protection Is Over: EVA-3S Was Not Flawed: Another Participantís View
  Presenters(s): Emmanuel M. Houdart, M.D.  
3:22 PM - 3:28 PM Do We Need A Trial Comparing Current Best Medical Therapy Against CEA And CAS: What Is The Status Of The TACIT Trial: Will It Ever Happen?
  Presenters(s): John H. Rundback, M.D., F.S.I.R., F.A.H.A.  
3:29 PM - 3:38 PM Panel Discussion
END OF SESSION XIV